28143658|t|Molecular docking simulation and anticancer assessment on human breast carcinoma cell line using novel bis(1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile) and bis(1,4-dihydropyrazolo[4',3':5,6]pyrano[2,3-b]pyridine-6-carbonitrile) derivatives
28143658|a|An efficient route for the synthesis of novel bis(1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile) derivatives is reported. The synthetic pathway involves one pot, synthesis of bis-aldehydes, malononitrile, and pyrazolone in the presence of pyridine. The anticancer activity of the synthesized products against MCF7, HEPG2, and A549 cell lines was assessed. Docking studies were performed and indicated the best binding mode compared to the standard ligand sorafenib.
28143658	0	28	Molecular docking simulation	T063	C3494273
28143658	33	54	anticancer assessment	T061	C0920425
28143658	58	63	human	T016	C0086418
28143658	64	80	breast carcinoma	T191	C0678222
28143658	81	90	cell line	T025	C0007634
28143658	103	155	bis(1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile)	T121	C1254351
28143658	160	243	bis(1,4-dihydropyrazolo[4',3':5,6]pyrano[2,3-b]pyridine-6-carbonitrile) derivatives	T121	C1254351
28143658	247	256	efficient	T080	C0442799
28143658	257	262	route	T082	C0449444
28143658	271	280	synthesis	T052	C1883254
28143658	290	354	bis(1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile) derivatives	T121	C1254351
28143658	372	381	synthetic	T052	C1883254
28143658	382	389	pathway	T077	C1705987
28143658	408	417	synthesis	T052	C1883254
28143658	421	434	bis-aldehydes	T109	C0029224
28143658	436	449	malononitrile	T109	C0057889
28143658	455	465	pyrazolone	T109,T121	C0072664
28143658	485	493	pyridine	T109,T130	C0034251
28143658	499	518	anticancer activity	T061	C0920425
28143658	526	537	synthesized	T052	C1883254
28143658	538	546	products	T071	C1514468
28143658	555	559	MCF7	T025	C0596890
28143658	561	566	HEPG2	T025	C2717940
28143658	572	587	A549 cell lines	T025	C4277577
28143658	592	600	assessed	T052	C1516048
28143658	602	617	Docking studies	T170	C3494274
28143658	656	668	binding mode	T052	C1145667
28143658	701	710	sorafenib	T109,T121	C1516119